Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Shares Sold by Xact Kapitalforvaltning AB

Xact Kapitalforvaltning AB trimmed its holdings in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 33.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,865 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the period. Xact Kapitalforvaltning AB’s holdings in Intercept Pharmaceuticals were worth $432,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Squarepoint Ops LLC increased its holdings in shares of Intercept Pharmaceuticals by 3.6% during the fourth quarter. Squarepoint Ops LLC now owns 3,399 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 118 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Intercept Pharmaceuticals by 14.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 183 shares during the period. Hanseatic Management Services Inc. increased its holdings in shares of Intercept Pharmaceuticals by 12.1% during the first quarter. Hanseatic Management Services Inc. now owns 2,077 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 224 shares during the period. LPL Financial LLC increased its holdings in shares of Intercept Pharmaceuticals by 0.3% during the fourth quarter. LPL Financial LLC now owns 74,815 shares of the biopharmaceutical company’s stock valued at $7,541,000 after purchasing an additional 254 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Intercept Pharmaceuticals by 37.7% during the first quarter. PNC Financial Services Group Inc. now owns 938 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 257 shares during the period. 76.20% of the stock is currently owned by institutional investors.

ICPT stock traded down $1.75 during trading hours on Friday, hitting $79.89. 10,563 shares of the stock traded hands, compared to its average volume of 578,691. Intercept Pharmaceuticals Inc has a one year low of $73.01 and a one year high of $133.74. The stock has a market capitalization of $2.43 billion, a P/E ratio of -7.37 and a beta of 1.44. The company has a quick ratio of 3.72, a current ratio of 3.72 and a debt-to-equity ratio of 19.41.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.57) by ($0.46). Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. The company had revenue of $52.25 million during the quarter, compared to analyst estimates of $52.15 million. During the same quarter last year, the business earned ($3.22) EPS. The company’s revenue for the quarter was up 45.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Intercept Pharmaceuticals Inc will post -10.06 earnings per share for the current year.

In related news, Director Luca Benatti purchased 1,200 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was acquired at an average price of $83.50 per share, for a total transaction of $100,200.00. Following the transaction, the director now directly owns 7,556 shares of the company’s stock, valued at approximately $630,926. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paolo Fundaro sold 2,171 shares of the stock in a transaction on Friday, March 29th. The shares were sold at an average price of $107.45, for a total value of $233,273.95. Following the completion of the transaction, the director now owns 11,114 shares of the company’s stock, valued at approximately $1,194,199.30. The disclosure for this sale can be found here. Insiders sold a total of 6,733 shares of company stock valued at $660,470 in the last quarter. 4.90% of the stock is currently owned by corporate insiders.

A number of research analysts have recently commented on ICPT shares. Raymond James reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, February 14th. Wedbush set a $251.00 price target on Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 5th. BidaskClub lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 23rd. B. Riley reissued a “buy” rating and set a $169.00 price target (up from $155.00) on shares of Intercept Pharmaceuticals in a report on Thursday, February 28th. Finally, Citigroup raised their price target on Intercept Pharmaceuticals from $106.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, February 21st. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and seventeen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $145.67.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Modern Readers and is owned by of Modern Readers. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.modernreaders.com/news/2019/06/14/intercept-pharmaceuticals-inc-nasdaqicpt-shares-sold-by-xact-kapitalforvaltning-ab.html.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: Buy Rating

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.